Abstract
The optimal heparin dosing schedule to achieve rapid and therapeutic anticoagulation has not been established. The objective of this study is to determine whether an intravenous heparin dosing nomogram based on body weight achieves adequate anticoagulation more rapidly than a standard-care nomogram. Sixty-four patients requiring intravenous heparin treatment for acute coronary syndromes, but who did not receive thrombolytic therapy, were randomized to a standard-care nomogram in which heparin was given as a 5000 unit IV bolus followed by 1000 U/hr, or a weight adjusted nomogram in which heparin was given as an 80 U/ kg IV bolus and 18 U/kg/hr. Activated partial thromboplastin time (APTT) values were checked at 6,12,18, 24, and 48 hours and adjusted either by 100–200 U/hr (standard-care nomogram) or by 2–4 U/kg/hr (weight-based nomogram). Activated partial thromboplastin times were measured using a widely generalizable laboratory method. The primary goal was to achieve and maintain the APTT between 60 and 90 seconds. The median APTT values were higher in the weight adjusted group compared with the standard-care group at 6, 12, 18, 24, and 48 hours: 150 versus 83 (p=0.001), 100 versus 79 (p=0.09), 66 versus 61 (p=0.005), 63 versus 56 (p = 0.09), and 64 versus 56 (p=0.11). At 18 hours only 11% of patients in the weight-adjusted group had an APTT <61 compared with 26% in the standard-care nomogram (p=0.007). No major bleeding complications were noted in either group. A weight-adjusted heparin nomogram offers improved anticoagulation in the first 24 hours after heparin initiation compared with a standard-care nomogram in patients with acute coronary artery syndromes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.N Engl J Med 1986;315:1109–1114.
Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.N Engl J Med 1972;287:324–327.
Turpie AGG, Robinsin JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction.N Engl J Med 1989;320:352–357.
Hsia J, Kleiman N, Aguirre F, Chaitman BR, Roberts R, Ross AM for the HART Investigators. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: Relation.J Am Coll Cardiol 1992;20:31–35.
Arnout J, Simoons M, DeBono D, Rapold HJ, Collen D, Verstraete M. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rtpa).J Am Coll Cardiol 1992;20:513–519.
Kaplan K, Davison R, Parker M, Mayberry B, Feiereisel P, Salinger M. Role of heparin after intravenous thrombolytic therapy for acute myocardial infarction.Am J Cardiol 1987;59:241–244.
Landefeld CS, Cook EF, Flatley M, Weisberg M, Goodman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy.Am J Med 1987;82:703–713.
Bovill EG, Terrin ML, Stump C, et al. for the TIMI Investigators. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction.Ann Intern Med 1991;115:256–265.
Cannon CP, Becker RC, Loscalzo J, et al. for the TIMI 5 Investigators. Usefulness of APTT to predict bleeding for hirudin (and heparin).Circulation 1994;90:I-563.
Antman EM for the TIMI 9A Investigators. Hirudin in acute myocardial infarction safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial.Circulation 1994;90:1624–1630.
Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguetiza M. A standard heparin nomogram for the management of heparin therapy.Arch Intern Med 1991;151:333.
Elliott CG, Hiltunen SJ, Suchyta M, et al. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis.Arch Intern Med 1994;154:999–1004.
Gunnarsson PS, Sawyer WT, Montague D, Williams DL, Dupuis RE, Caiola SM. Appropriate use of heparin.Arch Intern Med 1995;155:526–532.
Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a “standard care” nomogram.Ann Intern Med 1993;199:874–881.
Flaker GC, Bartolozzi J, Davis V, McCabe C, Cannon CP, for the TIMI 4 Investigators. Use of a standard heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction.Arch Intern Med 1994;154:1492–1495.
Braunwald E, Jones RH, Mark DB, et al. Diagnosing and managing unstable angina.Circulation 1994;90:613–22.
Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy.Ann Intern Med 1993;119:104–109.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hassan, W.M., Flaker, G.C., Feutz, C. et al. Improved anticoagulation with a weight-adjusted heparin nomogram in patients with acute coronary syndromes: A randomized trial. J Thromb Thrombol 2, 245–249 (1995). https://doi.org/10.1007/BF01062717
Issue Date:
DOI: https://doi.org/10.1007/BF01062717